As the Co-Founder and CEO of KiraGen Bio, I'm proud to lead a team of innovators dedicated to advancing CAR-T cell therapies for solid tumors. Together, we tackle the complex challenges of the tumor microenvironment and employ combinatorial gene editing techniques to transform cancer treatment. My journey into biotechnology has been driven by a decade of experience in gene editing, cell therapy, immunotherapy, mRNA therapeutics, infectious diseases, and vaccine design. At KiraGen, we combine advanced AI with a deep understanding of biology to develop targeted therapies that promise to transform patient care in oncology.Recently completed a MS/MBA in Biotechnology: Life Sciences at Harvard Business School and Harvard University Graduate School of Arts and Sciences. This program honed my ability to merge science with strategy and business, empowering me to navigate the complexities of biotech innovation and entrepreneurship effectively. My mission is to bridge the gap between groundbreaking scientific research and real-world applications, creating ventures that address critical medical needs and significantly improve human health.I am passionate about translating cutting-edge biomedical research into therapies that can change lives, driven by a belief in the power of science and technology to address the most pressing health challenges. At KiraGen Bio, we are committed to pushing the boundaries of what's possible in cancer treatment, and I am excited to lead our team towards achieving this vision.